29 Nov2013
29 Nov2013
Aus firm to raise $10 mn for multiple sclerosis drug
The fund will be used to conduct a placebo controlled phase 2B efficacy trial for progressive multiple sclerosis drug
Aus firm to raise $10 mn for multiple sclerosis drug
Australia medical biotechnology company, Innate Immunotherapeutics, plans to raise up to $10.93 million (A$12) million through an IPO of up to 60 million shares at $0.18 (A$0.20) per share. Firm commitments for $4.55 million (A$5 million) have been received, including $2.75 million (A$3 million) from Australian Ethical Smaller Companies Trust who have provided the cornerstone investment for the IPO.
